Different domains of the glucagon and glucagon‐like peptide‐1 receptors provide the critical determinants of ligand selectivity
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Glucagon and glucagon‐like peptide‐1 (GLP‐1) are homologous peptide hormones with important functions in glucose metabolism. The receptors for glucagon and GLP‐1 are homologous family B G‐protein coupled receptors. The GLP‐1 receptor amino‐terminal extracellular domain is a major determinant of glucagon/GLP‐1 selectivity of the GLP‐1 receptor. However, the divergent residues in glucagon and GLP‐1 that determine specificity for the GLP‐1 receptor amino‐terminal extracellular domain are not known. Less is known about how the glucagon receptor distinguishes between glucagon and GLP‐1. We analysed chimeric glucagon/GLP‐1 peptides for their ability to bind and activate the glucagon receptor, the GLP‐1 receptor and chimeric glucagon/GLP‐1 receptors. The chimeric peptide GLP‐1(7–20)/glucagon(15–29) was unable to bind and activate the glucagon receptor. Substituting the glucagon receptor core domain with the GLP‐1 receptor core domain (chimera A) completely rescued the affinity and potency of GLP‐1(7–20)/glucagon(15–29) without compromising the affinity and potency of glucagon. Substituting transmembrane segment 1 (TM1), TM6, TM7, the third extracellular loop and the intracellular carboxy‐terminus of chimera A with the corresponding glucagon receptor segments re‐established the ability to distinguish GLP‐1(7–20)/glucagon(15–29) from glucagon. Corroborant results were obtained with the opposite chimeric peptide glucagon(1–14)/GLP‐1(21–37). The results suggest that the glucagon and GLP‐1 receptor amino‐terminal extracellular domains determine specificity for the divergent residues in the glucagon and GLP‐1 carboxy‐terminals respectively. The GLP‐1 receptor core domain is not a critical determinant of glucagon/GLP‐1 selectivity. Conversely, the glucagon receptor core domain contains two or more sub‐segments which strongly determine specificity for divergent residues in the glucagon amino‐terminus. British Journal of Pharmacology (2003) 138, 787–794. doi:10.1038/sj.bjp.0705120
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Crystal Structure of Rhodopsin: A G Protein-Coupled Receptor
Palczewski, K., Kumasaka, T., Hori, T., Behnke, C. A., Motoshima, H., Fox, B. A., Trong, I. L., Teller, D. C., Okada, T., Stenkamp, R. E., et al. (2000) · Science · doi:10.1126/science.289.5480.739 · Cited by 5,637
Mojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Self-citationA new glucagon and GLP-1 co-agonist eliminates obesity in rodents
Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., Chaudhary, N., et al. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.209 · Cited by 641
Glucagon-Like Peptide 1/Glucagon Receptor Dual Agonism Reverses Obesity in Mice
Pocai, A., Carrington, P. E., Adams, J. R., Wright, M., Eiermann, G., Zhu, L., Du, X., Petrov, A., Lassman, M. E., Jiang, G., et al. (2009) · Diabetes · doi:10.2337/db09-0278 · Cited by 409
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors
Hoare, S. R. J. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03370-2 · Cited by 379
Underwood, C. R., Garibay, P., Knudsen, L. B., Hastrup, S., Peters, G. H., Rudolph, R., & Reedtz-Runge, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.033829 · Cited by 295
Self-citationThe structure and function of the glucagon‐like peptide‐1 receptor and its ligands
Donnelly, D. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01687.x · Cited by 292
Crystal Structure of the Ligand-bound Glucagon-like Peptide-1 Receptor Extracellular Domain
Runge, S., Thøgersen, H., Madsen, K., Lau, J., & Rudolph, R. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708740200 · Cited by 291
Self-citationSmall-molecule agonists for the glucagon-like peptide 1 receptor
Knudsen, L. B., Kiel, D., Teng, M., Behrens, C., Bhumralkar, D., Kodra, J. T., Holst, J. J., Jeppesen, C. B., Johnson, M. D., de Jong, J. C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605701104 · Cited by 232
Self-citationThe molecular pharmacology of glucagon agonists in diabetes and obesity
Novikoff, A., & Müller, T. D. (2023) · Peptides · doi:10.1016/j.peptides.2023.171003 · Cited by 82
“Specificity to the GcgR and GLP-1R is largely determined by the ligand’s C-terminal sequence interaction with the receptor’s N-terminal extracellular domain (ECD) [155].”
Ahrén, B., Yamada, Y., & Seino, Y. (2021) · Peptides · doi:10.1016/j.peptides.2020.170434 · Cited by 12
Metadata
- Authors
- Runge, S., Wulff, B. S., Madsen, K., Bräuner‐Osborne, H., & Knudsen, L. B.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2003-03
- Volume
- 138
- Issue
- 5
- Pages
- 787-794
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2052693157
- Cited by
- 133
- References
- 2
- FWCI
- 1.07
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.